Drugs Made In America Acquisition Corp. (DMAAU) Common Equity (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Common Equity came in at -$7.3 million in Q4 2025, down 2866.77% YoY from $262544.0 in Q4 2024, and down 1293.12% on a QoQ basis from $608822.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Common Equity (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Common Equity data on file, last reported at -$7.3 million in Q4 2025.
- Quarterly Common Equity fell 2866.77% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (down 2866.77% YoY) and the FY2025 annual result came in at -$7.3 million, down 2866.77% from the prior year.
- Common Equity eased to -$7.3 million in Q4 2025, from $608822.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $608822.0 in Q3 2025 to a low of -$7.3 million in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | 608,822.00 |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Dec 31, 2024 | -244,845.00 |